René Swanink - Concepedia

Concepedia

Author

René Swanink

Bristol-Myers Squibb (United States)

Also Known As

R. Swanink, Rene Swanink, Rene swanink, René Swanink

26

Publications

1.7K

Citations

14

H-Index

34

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Belgium)Otsuka (United States)Innsbruck Medical University Dana-Farber Cancer Institute

RS

About

René Swanink is an author at Bristol-Myers Squibb (United States) specializing in medicine, psychopharmacology, and psychiatry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	576
2	Social Sciences	3	3	414
3	Health Sciences	2	2	134
4	Immunology	2	2	37
5	Gastroenterology	1	1	11

René Swanink

×

15

Publications

1.7K

Citations

14

H-Index

	Year	Citations
The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder Robert Berman, Ronald N. Marcus, René Swanink, The Journal of Clinical Psychiatry	2007	402
Aripiprazole Augmentation in Major Depressive Disorder: <i>A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants</i> Robert Berman, Maurizio Fava, Michael E. Thase, CNS Spectrums	2009	256
Effectiveness of aripiprazole v. Haloperidol in acute bipolar mania Eduard Vieta, Michel Bourin, Raymond Sanchez, The British Journal of Psychiatry	2005	173
Aripiprazole for the Treatment of Psychoses in Institutionalized Patients With Alzheimer Dementia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Assessment of Three Fixed Doses Jacobo Mintzer, Larry E. Tune, Christopher D. Breder, American Journal of Geriatric Psychiatry NeuropsychologyAlzheimer's DiseasePsychiatryMedicineDementia	2007	157
Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease Peter Paul De Deyn, Dilip V. Jeste, René Swanink, Journal of Clinical Psychopharmacology Psychotropic MedicationPsychopharmacologyNeuropsychiatryPharmacotherapySocial Sciences	2005	150
A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease Joel E. Streim, Anton P. Porsteinsson, Christopher D. Breder, American Journal of Geriatric Psychiatry Alzheimer's DiseasePsychiatryPsychotropic MedicationDementiaPharmacology	2008	114
A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia W. Wolfgang Fleischhacker, Robert D. McQuade, Ronald N. Marcus, Biological Psychiatry PsychiatryPsychotic DisorderMedicinePsychotropic MedicationPsychopharmacology	2008	107
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial Lia Gore, Pamela Kearns, Maria Lucia de Martino, Journal of Clinical Oncology	2018	97
Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage<sup>®</sup> XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies Ken Fujioka, Ronald Brazg, Itamar Raz, Diabetes Obesity and Metabolism	2004	71
Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study Edward Keystone, Joel M. Kremer, Anthony S. Russell, Annals of the Rheumatic Diseases	2012	53

Page 1